Toxicology testing

Avalon GloboCare’s Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States

Retrieved on: 
Wednesday, July 19, 2023
Aetna, CAP, COVID-19, Genex Power, Genetic testing, Cigna, National Health Laboratory Service, Medicare, LSM, MSA, Laboratory, Master service agreement, Others, LC-MS, Instrumental chemistry, MSO, UnitedHealth Group, Toxicology testing, Pharmaceutical industry, Medicaid

FREEHOLD, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has signed an exclusive Master Service Agreement (“MSA”) with GeneX Laboratory Professional Corp. (“GeneX”). Avalon owns a 40% interest in LSM.

Key Points: 
  • Genex is a CLIA-certified and CAP-accredited laboratory located in Orange County, California that has been dormant and seeking a partner to utilize their valuable license networks.
  • Those tests will now be performed utilizing the LSM infrastructure and resources providing significant expansion opportunity for LSM to perform services through in-network insurance providers previously unavailable.
  • GeneX provides top-tier, comprehensive laboratory testing services and works with major providers in addition to Medicaid in 21 states.
  • By leveraging LSM’s experience and infrastructure, we expect to achieve significant synergies with respect to revenue growth and market shares,” concluded Dr. Jin.

AGCO issues $70,000 in monetary penalties to three internet gaming operators for offering uncertified slot games

Retrieved on: 
Thursday, April 20, 2023
Register, LAT, Standard, LeoVegas, Internet, ITL, Registrar, Offence against the person, Alcohol, Toxicology testing, Gambling, AGCO, Administrative Monetary Penalty, Ridesharing, Accessibility for Ontarians with Disabilities Act, 2005, Tribunals Ontario

In addition, contrary to Standard 1.22, the uncertified games that Mobile Incorporated Limited allegedly provided were from suppliers who are not registered with the AGCO.

Key Points: 
  • In addition, contrary to Standard 1.22, the uncertified games that Mobile Incorporated Limited allegedly provided were from suppliers who are not registered with the AGCO.
  • The Standards were put in place to protect Ontarians from potential harms while ensuring game integrity and fairness.
  • “The AGCO holds all registered operators to high standards of responsible gambling, player protection and game integrity, and monitors their activities in the interest of Ontarians.
  • A critical feature of our regulatory framework requires operators to only offer games that are from registered gaming suppliers and have been certified by an AGCO-registered independent testing laboratory to meet the highest standards of game integrity.

Global Preclinical CRO Market Report 2022: Increase in R&D Budget for Drug Development Presents Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 23, 2022
Health, General Health, Decision-making, Application, Research, Diabetes, Investment, Degenerative disease, Mergers and acquisitions, Royal Belfast Academical Institution, Strategic management, USD, Business Growth Fund, Value, CAGR, Customer support, Government, Use, Market share analysis, News, Gaps, Acquisition, Growth, Toxicology testing, Toxicology, Weakness, Infection, Global, Collaborative partnership, Neurological disorder, Fine chemical, Retail, Bioanalysis

Based on End-user, the market was studied across Biopharmaceutical Companies, Government and Academic Institutes, and Medical Device Companies.

Key Points: 
  • Based on End-user, the market was studied across Biopharmaceutical Companies, Government and Academic Institutes, and Medical Device Companies.
  • Based on Application, the market was studied across Cardiovascular Diseases, Central Nervous System Disorders, Diabetes, Immunological Disorders, Infectious Diseases, Oncology, and Respiratory Diseases.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • The United States is further studied across California, Florida, Illinois, Massachusetts, Minnesota, New Jersey, New York, Ohio, Pennsylvania, and Texas.

Global 3D Cell Culture Market (2022 to 2027) - Emergence of Microfluidics-Based 3D Cell Culture Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Science, Other Science, Research, Research, Ansoff Matrix, Observation, Microfluidics, Toxicology testing, Porter's five forces analysis, Biotechnology, Cell culture, Investment, Drug discovery, Growth, Geography, Emotion, Risk, Magnetism, Medication, COVID-19, Market development, Industry, Competitive analysis, Cell, SWOT, CAGR, USD, Impact, 3D printing, Retail, Risk management, Pharmaceutical industry, Application

Market dynamics are forces that impact the prices and behaviors of the Global 3D Cell Culture Market stakeholders.

Key Points: 
  • Market dynamics are forces that impact the prices and behaviors of the Global 3D Cell Culture Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global 3D Cell Culture Market.
  • The report analyses the Global 3D Cell Culture Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • By Product, the market is classified into Scaffold-Based 3D Cell Cultures, Scaffold-Free 3D Cell Cultures, Microfluidics-Based 3D Cell Cultures, and Magnetic & Bioprinted 3D Cell Cultures.

Global Preclinical CRO Market Report 2022-2030: Toxicology Testing, Bioanalysis & DMPK Studies - Rising R&D Offshoring & Outsourcing Trends - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Pharmaceutical, Science, Health, Research, Disease, PDO, Investment, Wuxi, Vaccine, Government, USD, COVID-19, Research, Toxicology testing, IND, CRO, Bioanalysis, CAGR, Growth, Academic institution, Investigational New Drug, Fine chemical, Pharmaceutical industry, Medical device

The "Preclinical CRO Market Size, Share & Trends Analysis Report by Service (Toxicology Testing, Bioanalysis & DMPK Studies), by End Use (Biopharmaceutical Companies, Government & Academic Institutes), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Preclinical CRO Market Size, Share & Trends Analysis Report by Service (Toxicology Testing, Bioanalysis & DMPK Studies), by End Use (Biopharmaceutical Companies, Government & Academic Institutes), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global preclinical CRO market size is expected to reach USD 9.67 billion by 2030, expanding at a CAGR of 7.9%.
  • The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends.
  • The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market during the forecast period.

The United States Preclinical CRO Market is Projected to Grow at a Compound Annual Growth Rate of 8.87% Between 2022 and 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 24, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Infection, CAD, Degenerative disease, R, Certification, Compound annual growth rate, EUR, Investment, Diabetes, State, USD, COVID-19, Research, Toxicology testing, JPY, Neurological disorder, Toxicology, Technology, AUD, GBP, CAGR, CHF, Government, Academic institution, Fine chemical, Cryptocurrency, Bioanalysis, Application

The United States Preclinical CRO Market size was estimated at USD 1,168.70 million in 2021 and expected to reach USD 1,252.61 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.87% to reach USD 1,946.51 million by 2027.

Key Points: 
  • The United States Preclinical CRO Market size was estimated at USD 1,168.70 million in 2021 and expected to reach USD 1,252.61 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.87% to reach USD 1,946.51 million by 2027.
  • Which are the products/segments/applications/areas to invest in over the forecast period in the United States Preclinical CRO Market?
  • What is the market share of the leading vendors in the United States Preclinical CRO Market?
  • What modes and strategic moves are considered suitable for entering the United States Preclinical CRO Market?

Genetic Toxicology Testing (Assays, Reagents & Consumables, Services) Market with COVID-19 Impact Analysis - Global Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 5, 2021
Health, Genetics, Science, Pharmaceutical, Research, Toxicology, Natural sciences, Animal testing, Tests, Toxicology testing, Physical sciences, Assay, Cosmetics, Academic disciplines

The "Global Genetic Toxicology Testing Market with COVID-19 Impact Analysis by Product (Assays, Reagents & Consumables, Services), Application (Healthcare Industry, Food Industry, Cosmetics Industry, Agriculture Industry) and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genetic Toxicology Testing Market with COVID-19 Impact Analysis by Product (Assays, Reagents & Consumables, Services), Application (Healthcare Industry, Food Industry, Cosmetics Industry, Agriculture Industry) and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The world's genetic toxicology testing market is projected to reach USD 2 billion by 2025 from USD 1.2 billion in 2020, at a CAGR of 10.2%.
  • Growth in this market is primarily driven by increased pharmaceutical research activities, opposition to animal testing, and R&D on early toxicity detection.
  • Based on product, the genetic toxicology testing market is segmented into reagents & consumables, assays, and services.

Genetic Toxicology Testing Market worth $2.0 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, December 14, 2020
Laboratory techniques, Natural sciences, Physical sciences, Chemistry, Animal testing, Tests, Toxicology testing, Alternatives to animal testing, Assay, Toxicology, Toxicity, In vitro

We estimate that the genetic toxicology testing adoption, along with personalized medicine, will grow at a stable pace in the next five years.

Key Points: 
  • We estimate that the genetic toxicology testing adoption, along with personalized medicine, will grow at a stable pace in the next five years.
  • Based on product, the genetic toxicology testing market is segmented into reagents & consumables, assays, and services.
  • The Asia Pacific market is expected to grow at the highest CAGR from 2020 to 2025.
  • In Vitro Toxicity Testing Market by Product (Assay (Western Blot, Tissue Culture),Equipment, Assay Reagent, Software), Toxicity Endpoints (ADME, Skin Irritation, Corrosion),Industry (Pharmaceutical, Cosmetics)-COVID-19 Impact - Global Forecast to 2025

Genetic Toxicology Testing Market worth $2.0 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, December 14, 2020
Laboratory techniques, Natural sciences, Physical sciences, Chemistry, Animal testing, Tests, Toxicology testing, Alternatives to animal testing, Assay, Toxicology, Toxicity, In vitro

We estimate that the genetic toxicology testing adoption, along with personalized medicine, will grow at a stable pace in the next five years.

Key Points: 
  • We estimate that the genetic toxicology testing adoption, along with personalized medicine, will grow at a stable pace in the next five years.
  • Based on product, the genetic toxicology testing market is segmented into reagents & consumables, assays, and services.
  • The Asia Pacific market is expected to grow at the highest CAGR from 2020 to 2025.
  • In Vitro Toxicity Testing Market by Product (Assay (Western Blot, Tissue Culture),Equipment, Assay Reagent, Software), Toxicity Endpoints (ADME, Skin Irritation, Corrosion),Industry (Pharmaceutical, Cosmetics)-COVID-19 Impact - Global Forecast to 2025

Sinclair Research Announces Successful Validation of GLP Ototoxicity Testing Services

Retrieved on: 
Tuesday, June 30, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Health, Articles, Pharmaceutical industry, Animal testing, Validity, Tests, Toxicology, Toxicology testing, Ototoxicity, Validation, Medical research, Sinclair Research, Turner Scientific

Sinclair Research, a leading provider of nonclinical contract research services, today announced completion of successful validation of GLP ototoxicity testing services in partnership with Turner Scientific, an industry leader specializing in nonclinical hearing research.

Key Points: 
  • Sinclair Research, a leading provider of nonclinical contract research services, today announced completion of successful validation of GLP ototoxicity testing services in partnership with Turner Scientific, an industry leader specializing in nonclinical hearing research.
  • Sinclairs validated GLP ototoxicity testing services provide drug developers with more research options, Andy Brown, Sinclair Researchs Vice President of Commercial Operations said.
  • As a result of our partnership with Turner Scientific, Sinclair Research is one of the only CROs that can offer GLP auditory safety research services, and we are excited to offer GLP ototoxicity testing along with IND-enabling nonclinical toxicology services at a single-site CRO.
  • These successful validation studies provided accurate, high-confidence data and conclusively demonstrated the high-quality auditory research support that Turner Scientific and Sinclair Research are able to provide drug developers.